INVESTOR ALERT: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market share growth during a specified class period [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation, and it includes purchasers of Boston Scientific common stock from July 23, 2025, to February 3, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Boston Scientific and its executives made false statements and failed to disclose critical information about the company's financial health and market competition [3]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year ago [4]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year [4]. - The adjusted EPS for Q4 2025 was $0.80, compared to $0.70 a year ago, and for the full year, it was $3.06, compared to $2.51 a year ago [4]. - Following the financial results announcement, Boston Scientific's stock price fell by more than 17% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Boston Scientific common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [5]. - An investor's potential recovery is not contingent upon serving as lead plaintiff [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, significantly more than any other law firm [6].